

UROTHELKARZINOM

STELLAR 002: A dose-escalation and expansion study of the safety and efficacy of XL092 in combination with immuno- oncology agents in subjects with unresectable advanced or metastatic solid tumors / urothelial carcinoma post EV and ICI

Open

PROSTATAKARZINOM

ARASTEP: A randomized, double-blind, placebo-controlled Phase 3 study of Darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer (Sponsor: Bayer)

Closed for recruitment

EVO-PAR-01: A randomised, double-blind, placebo-controlled, phase III study of AZD5305 in combination with physician's choice new hormonal agents in participants with metastatic castration-sensitive prostate cancer with and without HRRm (Sponsor: AstraZeneca)

Closed for recruitment

EVO-PAR-02: A randomized, double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (Sponsor: AstraZeneca)

Open

XALIENCE: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Open

XALUTE: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Closed for recruitment

Prostatae cancer outcomes – compare & reduce variation in DKG-zertifizierten Prostatakrebszentren

NIERENZELLKARZINOM

STELLAR 002: A dose-escalation and expansion study of the safety and efficacy of XL092 in combination with immuno- oncology agents in subjects with unresectable advanced or metastatic solid tumors / ccRCC (1st line)

Open

Stand: Juni 2026